The global pharmaceutical market continues on a trend of several consecutive years of slowing, single digit sales growth and pressure on earnings due to the lack of large new products to replace the current blockbusters going off patent. As such, companies are looking for ways to be even more effective and efficient in their sales/marketing and R&D investments, while capitalizing on the highest opportunities for growth such as emerging global markets and specialty-driven therapeutic categories with high unmet medical need.

Now more than ever, pharmaceutical and bio-tech companies are focusing on their pipelines as important sources of growth. At the same time, they and are under great scrutiny from the regulatory environment to ensure the full risk/benefit profile of each new product is fully characterized, and the investment community is demanding accurate information about the potential value of the pipeline. In both contexts it’s critical not to under or overestimate the potential of the compound to ensure clinical, regulatory, and commercial success for the benefit of patients who need the innovation in treatment.

BASES consultants provide services that help companies achieve growth through successful innovation.